We expect to provide additional announcements on our product development timeline in the coming months.” We believe our breakthrough platform technology has the ability to become the standard of care in emergency medicine and cardiology, serving a $10 billion addressable and underserved market for MI detection. Our telemedicine solution can be used by patients at home to help their physicians assess whether chest pain is the result of a heart attack (MI) and is supported by robust clinical data and a strong IP portfolio. Vajdic continued, “Development of our FDA-ready products for our Telehealth and ER Software Tool solutions are moving ahead on a well-defined regulatory pathway. The net proceeds to HeartBeam from the offering amounted to $14.9 million, bringing our Septempro-forma cash balance to approximately $15.7 million.”ĭr.
“We believe our Nasdaq listing will help elevate the Company's public profile, expand our shareholder base, improve liquidity and enhance shareholder value. “The third quarter of 2021 was a significant milestone for our company with our transition to a public company and the addition of new capital to accelerate our commercialization path,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. Presented ED-MID diagnostics software research data at the 43 rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society in November 2021. The Company’s common stock and warrants commenced trading on Nasdaq Capital Market under the ticker symbols “BEAT” and “BEATW”, respectively. The Company’s Units separated into common stock and warrants upon issuance. Net proceeds raised in HeartBeam’s IPO were $14.9 million, after deducting underwriting discounts and commissions.
On November 15, 2021, successfully completed its initial public offering (IPO), selling 2,750,000 units (the “Units”) to the public at $6.00 per Unit, comprised of one share of common stock and one five-year warrant to acquire a share of common stock with an exercise price of $6.00 per share. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, has reported its financial and operational results for the third quarter and nine months ended September 30, 2021. SANTA CLARA, Calif.-( BUSINESS WIRE)- HeartBeam, Inc.
0 kommentar(er)
